MVA.tHIVconsv3

BIOLOGICAL3 trials

Sponsors

University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV VaccineHIV-1 InfectionHIV-1-infection

Phase 1

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

CompletedNCT03844386

University of North Carolina, Chapel HillHIV-1 Infection

Start: 2019-04-22End: 2022-04-04Updated: 2022-08-09

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

CompletedNCT05604209

University of North Carolina, Chapel HillHIV-1-infection, HIV Vaccine

Start: 2022-10-13End: 2025-01-10Updated: 2025-08-24

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

RecruitingNCT06071767

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1-infection

Start: 2024-04-01End: 2029-08-01Target: 36Updated: 2026-02-09

Related Papers

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Nature Communications2025-03-0416 citations

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

Journal of Immunology Research2024-01-0112 citations